AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25267153 — intervention group
Group type: COMPARATOR
Intervention: HBsAg alone
Number of subjects: 16
Study 22332874 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal T1D
Number of subjects: 40
Study 22332874 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro insulin stimulation in infants with maternal T1D
Number of subjects: 40
Study 22332874 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal T1D with PTPN22 allele
Number of subjects: 40
Study 22332874 — intervention group
Group type: COMPARATOR
Intervention: Infants born to unaffected mothers
Number of subjects: 40
Study 20504126 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurements
Number of subjects: 400
Study 20504126 — intervention group
Group type: COMPARATOR
Intervention: Casual/Clinic Blood Pressure (CBP) measurements
Number of subjects: 400
Study 18538113 — intervention group
Group type: COMPARATOR
Intervention: ZyrtecA (reference formulation)
Number of subjects: 18
Study 18538113 — intervention group
Group type: EXPERIMENTAL
Intervention: RyvelA (test formulation)
Number of subjects: 18
Study 16005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded condition (10% body mass)
Number of subjects: 20
Study 16005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded condition
Number of subjects: 20
Study 16005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period (loaded)
Number of subjects: 20
Study 16005554 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period (unloaded)
Number of subjects: 20
Study 12464754 — intervention group
Group type: EXPERIMENTAL
Intervention: six telephone intervention sessions on safety behaviors
Number of subjects: 75
Study 12464754 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 75
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*0701 allele
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1*0201 allele
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*0701-DQA1*0201 haplotype
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1*0103 allele
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*0603 allele
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*13-DQA1*0501-3-DQB1*0301 haplotype
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*13-DQA1*0103-DQB1*0603 haplotype
Number of subjects: 88
Study 10351973 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD patients
Number of subjects: 88
Study 8751234 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 7 days
Number of subjects: 8
Study 8751234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 7 days
Number of subjects: 8
Study 8751234 — intervention group
Group type: COMPARATOR
Intervention: Test meal
Number of subjects: 8
Study 1726637 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker treatment
Number of subjects: 0
Study 1726637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6414271 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque, 300 mg l/ml
Number of subjects: 12
Study 6414271 — intervention group
Group type: COMPARATOR
Intervention: Amipaque, 300 mg l/ml
Number of subjects: 12
Study 31022446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone (intervention group)
Number of subjects: 0
Study 31022446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 28174415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 194
Study 28174415 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 194
Study 25658497 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 345
Study 25658497 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI/TCA
Number of subjects: 345
Study 24356339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of integrated DNA repair OMA score
Number of subjects: 192
Study 24356339 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of integrated DNA repair OMA score
Number of subjects: 192
Study 21919922 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg daily)
Number of subjects: 17
Study 21919922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19368417 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 microg
Number of subjects: 1964
Study 19368417 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/9 microg
Number of subjects: 1964
Study 19368417 — intervention group
Group type: COMPARATOR
Intervention: Formoterol DPI 9 microg
Number of subjects: 1964
Study 19368417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1964
Study 17404491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 17404491 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated vitamin D(3) analogues
Number of subjects: 0
Study 17404491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(2) analogues
Number of subjects: 0
Study 15039349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated birds (DNA vaccine plasmid encoding the circumsporozoite protein of P. relictum)
Number of subjects: 3
Study 15039349 — intervention group
Group type: COMPARATOR
Intervention: Naïve birds
Number of subjects: 3
Study 15039349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated birds
Number of subjects: 3
Study 15039349 — intervention group
Group type: COMPARATOR
Intervention: Cages of naïve birds
Number of subjects: 3
Study 11174738 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II
Number of subjects: 1336
Study 11174738 — intervention group
Group type: COMPARATOR
Intervention: Carmeda BioActive Surface
Number of subjects: 1336
Study 9757855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy products containing up to 1200 mg/d of calcium
Number of subjects: 70
Study 9757855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no increase in calcium intake)
Number of subjects: 70
Study 8140876 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual stimulation of needles (MS)
Number of subjects: 40
Study 8140876 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical low frequency stimulation at 2 Hz (LF)
Number of subjects: 40
Study 8140876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation at 80 Hz (HF)
Number of subjects: 40
Study 8140876 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 40
Study 2903936 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine antagonist
Number of subjects: 18
Study 2903936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30208868 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized messages through an Interactive Voice Response (IVR) system
Number of subjects: 795
Study 30208868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother and Baby Affairs (MBA) workshops
Number of subjects: 795
Study 30208868 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflet with details on glucose testing and follow-up
Number of subjects: 795
Study 27526661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3048
Study 27526661 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3048
Study 26506383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g daily for six months)
Number of subjects: 50
Study 26506383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23021099 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 21383836 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending piano melody exposure during the 35th, 36th, and 37th weeks of gestation, twice daily for 3 weeks.
Number of subjects: 50
Study 21383836 — intervention group
Group type: COMPARATOR
Intervention: Ascending control piano melody.
Number of subjects: 50
Study 18316340 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate or unclear allocation concealment
Number of subjects: 1346
Study 18316340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of blinding
Number of subjects: 1346
Study 16502765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat fed (HFF)
Number of subjects: 45
Study 16502765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat fed (LFF)
Number of subjects: 45
Study 16502765 — intervention group
Group type: COMPARATOR
Intervention: Fasting (reference)
Number of subjects: 45
Study 15715403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 20
Study 15715403 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 10674956 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) 0.12% mouthrinse
Number of subjects: 28
Study 10674956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) combined with sodium perborate (CHX+PER)
Number of subjects: 28
Study 9541360 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium iodate added to irrigation water (10-80 microg/l) for 2-4 weeks
Number of subjects: 37000
Study 8309707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulation of the teeth at varying temperatures from +30°C to ‐30°C
Number of subjects: 12
Study 2880214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycerol (500 ml of a 10% solution in physiological saline)
Number of subjects: 173
Study 2880214 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (500 ml administered intravenously)
Number of subjects: 173
Study 2880214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 173
Study 30069238 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA scan for diagnosing osteoporosis
Number of subjects: 100
Study 30069238 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA scan
Number of subjects: 100
Study 26925523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 132
Study 26925523 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 132
Study 25557266 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 125
Study 25557266 — intervention group
Group type: COMPARATOR
Intervention: Observation (Obs)
Number of subjects: 125
Study 25557266 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of D+P
Number of subjects: 125
Study 25557266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 125
Study 23852947 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine
Number of subjects: 38
Study 23852947 — intervention group
Group type: COMPARATOR
Intervention: lamivudine
Number of subjects: 38
Study 20627916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening
Number of subjects: 1284
Study 20627916 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1284
Study 18261131 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk magnitude 50%
Number of subjects: 180
Study 18261131 — intervention group
Group type: COMPARATOR
Intervention: Risk magnitude 3%
Number of subjects: 180
Study 18261131 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk provenance: mutation negative
Number of subjects: 180
Study 18261131 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped icon display
Number of subjects: 180
Study 18261131 — intervention group
Group type: COMPARATOR
Intervention: Risk provenance: family history
Number of subjects: 180
Study 18261131 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk magnitude 6%
Number of subjects: 180
Study 16189256 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 37
Study 16189256 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 37
Study 16189256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12578874 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-nlEF patients
Number of subjects: 10
Study 12578874 — intervention group
Group type: COMPARATOR
Intervention: Age- and blood pressure-matched controls
Number of subjects: 10
Study 10656116 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Anda-TB enzyme immunoassay test
Number of subjects: 0
Study 8777677 — intervention group
Group type: EXPERIMENTAL
Intervention: PN+selenium (3 micrograms/kg/day of selenious acid)
Number of subjects: 38
Study 8777677 — intervention group
Group type: COMPARATOR
Intervention: PN-selenium (non-supplemented)
Number of subjects: 38
Study 8777677 — intervention group
Group type: EXPERIMENTAL
Intervention: PN+selenium
Number of subjects: 38
Study 8777677 — intervention group
Group type: COMPARATOR
Intervention: Term breastfed infants
Number of subjects: 38
Study 2050539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1500 mg daily
Number of subjects: 298
Study 2050539 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 298
Study 6670591 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (10 to 15 ml, 180 mg I/ml)
Number of subjects: 30
Study 30762691 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection or amputation
Number of subjects: 200
Study 30762691 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Number of subjects: 200
Study 30762691 — intervention group
Group type: COMPARATOR
Intervention: No primary tumor resection
Number of subjects: 200
Study 30249462 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR (Transcatheter Aortic Valve Replacement)
Number of subjects: 797
Study 30249462 — intervention group
Group type: COMPARATOR
Intervention: SAVR (Surgical Aortic Valve Replacement)
Number of subjects: 797
Study 30249462 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 797
Study 30249462 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 797
Study 26758251 — intervention group
Group type: EXPERIMENTAL
Intervention: DE + allergen (DEA)
Number of subjects: 12
Study 26758251 — intervention group
Group type: EXPERIMENTAL
Intervention: FAA
Number of subjects: 12
Study 26758251 — intervention group
Group type: COMPARATOR
Intervention: Filtered air + saline (FAS)
Number of subjects: 12
Study 24652053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention + placebo (DIP)
Number of subjects: 70
Study 24652053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention + supplementation of omega 3 (DIS3)
Number of subjects: 70
Study 24652053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention + placebo + physical activity (DIPE)
Number of subjects: 70
Study 24652053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention + physical activity + supplementation of omega 3 (DIS3PE)
Number of subjects: 70
Study 24652053 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 70
Study 23299064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 250 mg twice daily for 10 days (n=57)
Number of subjects: 99
Study 23299064 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 500/125 mg three times daily for 10 days (n=42)
Number of subjects: 99
Study 20410427 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound and MR angiography measurements (renal length, total and cortical volumes, resistive index)
Number of subjects: 51
Study 20410427 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal length and cortical volume weighted by resistive index
Number of subjects: 51
Study 20410427 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of renal length-resistive index product less than 7 cm
Number of subjects: 51
Study 20410427 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value of 52 mL/m(2) for cortical renal volume-resistive index product
Number of subjects: 51
Study 17234558 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalamine 2.4 g/day given twice daily
Number of subjects: 280
Study 17234558 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalamine 4.8 g/day given once daily
Number of subjects: 280
Study 17234558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 15870503 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole
Number of subjects: 529
Study 15870503 — intervention group
Group type: COMPARATOR
Intervention: 20 mg esomeprazole
Number of subjects: 529
Study 12140806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC), n = 51
Number of subjects: 98
Study 12140806 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC), n = 47
Number of subjects: 98
Study 10676544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing randomized preventive trials
Number of subjects: 0
Study 8653531 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d of sertraline
Number of subjects: 53
Study 8653531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8653531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 53
Study 2231066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 344125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 26
Study 344125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30007333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.018-inch slot bracket system
Number of subjects: 187
Study 30007333 — intervention group
Group type: COMPARATOR
Intervention: 0.022-inch slot bracket system
Number of subjects: 187
Study 28077114 — intervention group
Group type: EXPERIMENTAL
Intervention: the worksite cafeteria 2.0 intervention (12-week duration)
Number of subjects: 34
Study 28077114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 26729950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct statin therapy with DMARDs
Number of subjects: 60
Study 26729950 — intervention group
Group type: COMPARATOR
Intervention: Conventional DMARD therapy
Number of subjects: 60
Study 24410484 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 25 mg
Number of subjects: 120
Study 24410484 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 120
Study 21849651 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 9771
Study 21849651 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10
Number of subjects: 9771
Study 21849651 — intervention group
Group type: EXPERIMENTAL
Intervention: eotaxin-1
Number of subjects: 9771
Study 21849651 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 9771
Study 21849651 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES and IP-10 (combined in multivariate model)
Number of subjects: 9771
Study 19268890 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 microg dexamethasone DDS
Number of subjects: 41
Study 19268890 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone DDS
Number of subjects: 41
Study 19268890 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 41
Study 19268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 41
Study 19268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (700 microg)
Number of subjects: 41
Study 19268890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (350 microg)
Number of subjects: 41
Study 17710010 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (n=17)
Number of subjects: 35
Study 17710010 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (n=18)
Number of subjects: 35
Study 17710010 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women, n=30)
Number of subjects: 35
Study 17710010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (combined treatment)
Number of subjects: 35
Study 16162697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid for 24 weeks
Number of subjects: 207
Study 16162697 — intervention group
Group type: COMPARATOR
Intervention: Placebo, bid for 24 weeks
Number of subjects: 207
Study 12212780 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPAKINE CX516
Number of subjects: 0
Study 12212780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10455094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivazerol (oral administration over a two week period)
Number of subjects: 25
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective mood ratings
Number of subjects: 0
Study 7608352 — intervention group
Group type: COMPARATOR
Intervention: Prospective mood ratings
Number of subjects: 0
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional states
Number of subjects: 0
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure
Number of subjects: 0
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotions
Number of subjects: 0
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal determinants
Number of subjects: 0
Study 7608352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal determinants
Number of subjects: 0
Study 2611434 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Number of subjects: 60
Study 2611434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2611434 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 59012 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 0
Study 59012 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated subjects
Number of subjects: 0
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin monotherapy (15 mg)
Number of subjects: 14